AM-Pharma presents positive results of its Phase II clinical trial with Alkaline Phosphatase in Acute Kidney Injury

March 10 2010 | Category: Product

Alkaline Phosphatase improved renal function, reduced length of stay in Intensive Care, and could become First-in-Class drug in multi-billion market

Bunnik, The Netherlands, 10 March 2010. AM-Pharma B.V., the biopharmaceutical company, today announced positive results from its Phase II Acute Kidney Injury trial with Alkaline Phosphatase at ISICEM, one of the world’s leading Intensive Care conferences. The study showed that treatment of Acute Kidney Injury (AKI) with Alkaline Phosphatase results in improved renal function and reduced length of stay in Intensive Care. No drug currently exists to treat AKI, therefore Alkaline Phosphatase could become a “first in class” product in the market. The cost of managing AKI in the US is around $10 billion per year.

The key objective of the trial was to show improved kidney function in AKI patients treated with bovine Alkaline Phosphatase. Primary efficacy parameters were; dialysis requirement, creatinine clearance and serum creatinine. The trial objective was met and the results are both statistically significant and clinically relevant. The treatment was well tolerated and there were no safety concerns.

Statistical significant improvement was also reached on important secondary endpoints. Average stay in Intensive Care was significantly shorter for patients on Alkaline Phosphatase compared to patients on placebo. Also, the need for mechanical ventilation was significantly reduced.

In this double blind, placebo controlled, prospective clinical study in 36 patients with AKI secondary to sepsis, patients received Alkaline Phosphatase intravenously for 48 hours and were followed for 28 days. The multi-centre trial was conducted at critical care units in The Netherlands and Belgium.

A composite analysis of all primary renal function efficacy parameters, creatinine clearance, serum creatinine and dialysis requirement shows statistically significant improvement (p=0.005) compared to placebo. Renal creatinine clearance improved more than twice as fast in the treated group during the first 7 days, (p<0.02) resulting in normalization of creatinine clearance for the rest of the 28 days, compared to the placebo group, where creatinine clearance remained impaired (p<0.02).. There was a reduction of dialysis requirement after treatment with Alkaline Phosphatase compared to placebo (means: 10 hours vs 53 hours, p=0.08). Treatment with Alkaline Phosphatase resulted in shorter stay in ICU (11 days vs 25 days, p<0.02) and in reduced need for mechanical ventilation (3.9 days vs 6.0 days, p<0.03). Patients in the group treated with Alkaline Phosphatase were comparable at baseline to patients in the placebo group.

These results confirm the results of an earlier Phase II trial with bovine Alkaline Phosphatase in a similar patient population. The results of this first trial were published in Critical Care Medicine journal in February 2009.

Bart Wuurman, CEO commented: “With the results of our two trials we have shown convincingly that Alkaline Phosphatase is very promising as a safe and effective treatment of Acute Kidney Injury. Motivated by these positive results with bovine Alkaline Phosphatase, we are now switching to our proprietary recombinant human Alkaline Phosphatase for further development and commercialization. It is very exciting to be progressing with this novel drug, which could be the first treatment to be approved for Acute Kidney Injury, a condition with high incidence, high mortality and high cost burden to our healthcare system”.

AM-Pharma has now reported positive results with Alkaline Phosphatase in three Phase II clinical trials. In the two AKI trials Alkaline Phosphatase was given intravenously and in a third Phase II trial with Alkaline Phosphatase in severe Ulcerative Colitis, the drug was administered orally.

Download this press release (111 kB, pdf)


Latest News

October 24 2018
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
Read more.

March 9 2018
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Read more.

News Categories

Appointment
Investor
Product

Upcoming Events

For a full list of the events we will be attending this year
Click here.